Document:

OMER-EX10.24_ Leicester 8th & 9th Amendments

EXHIBIT 10.24
CONFIDENTIAL TREATMENT REQUESTED under 17 C.F.R. § 200.80(b)(4) and 240.24b-2

RESEARCH AND DEVELOPMENT AGREEMENT
EIGHTH AMENDMENT
This is an amendment effective 21 March 2012 (this “Amendment”) of the Exclusive License and Sponsored Research Agreement dated 10 June 2004 as last amended 
1 October 2011 (the “Agreement”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”).  All capitalized terms used in this Amendment shall have the same meaning as set forth in the Agreement unless otherwise defined below. 

In recognition of a temporary increase in scope of effort by Dr. Schwaeble and his laboratory staff during late 2011 and early 2012 related to the Sponsored Research, including the role of [†] and the [†], all of which are acknowledged to be included in the Joint IP under the Agreement, Omeros is willing to provide additional compensation for the Sponsored Research.  
Omeros therefore agrees that the in addition to the sum of [†] paid to Leicester for Sponsored Research during the eight year of the Sponsored Research Term payable in accordance with Section 2.5 of the Agreement, Omeros shall pay to Leicester the amount of [†] as a one-time payment, to be paid within thirty (30) days of a receipt of an invoice from Omeros.
All other provisions of the Agreement, including Sections 1 through 16 inclusive, as amended above, shall continue unchanged in full force and effect.  
This Amendment is accepted and acknowledged by each party, as of the effective date set forth herein above, through the signature of its authorized representative(s) below:
	
		
	OMEROS CORPORATION
	UNIVERSITY OF LEICESTER

	By:   /s/ Gregory A. Demopulos   
Name:  Gregory A. Demopulos, M.D.
	By:   /s/ Chris A. Jones   
Name:   Chris A. Jones

	Title:    Chairman & CEO
	Title:   Head of Research Commercialization   

	Date:   March 20, 2012
	Date:   November 20, 2012

† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
1

CONFIDENTIAL TREATMENT REQUESTED under 17 C.F.R. § 200.80(b)(4) and 240.24b-2

RESEARCH AND DEVELOPMENT AGREEMENT
NINTH AMENDMENT
This is a ninth amendment dated 1 September 2013 (this “Amendment”), and effective nunc pro tunc as of 1 October 2013 of the Exclusive License and Sponsored Research Agreement dated 10 June 2004 as previously amended 1 October 2005, 1 June 2007, 8 February 2008, 6 February 2009, 18 November 2009,  1 October 2010, 1 October 2011 and 21 March 2012 (the “Agreement”) between Omeros Corporation, a Washington corporation having a current principal place of business at 201 Elliott Avenue West, Seattle, WA 98119 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”).  All capitalized terms used in this Amendment shall have the same meaning as set forth in the Agreement unless otherwise defined below. 

Omeros and Leicester have continued to collaborate on research under the Agreement, and Leicester has provided to Omeros regular status reports on the progress of the Sponsored Research, and Omeros has provided Leicester regular status reports on the progress of its research and development efforts under the Agreement, through regular conference calls, typically on a weekly basis, between Omeros and Leicester researchers, in satisfaction of less frequent reports called for under the Agreement.  In view of progress to date, Omeros and Leicester have determined to extend the Sponsored Research Term under the Agreement through 30 September 2014.  
Omeros has previously paid Leicester the sum of [†] for research performed during the ninth year of the Sponsored Research Term, (i.e., 1 October 2012 through 30 September 2013), not yet reflected in a written amendment of the Agreement, as well as a one-time payment of [†] pursuant to an eighth amendment of the Agreement dated 21 March 2012.  Leicester has requested Omeros to increase the level of financial support during the tenth year of the Sponsored Research Term (i.e., 1 October 2013 through 30 September 2014), and Omeros and Leicester have agreed to expand the scope of Sponsored Research during the Sponsored Research Term to include exploration of the role of [†] and the [†], together with or independently of [†], all of which is agreed to be included in the Joint IP under the Agreement.  Omeros and Leicester therefore agree that the Agreement shall be amended as follows, with sections of this Amendment being numbered to match corresponding Sections of the Agreement.
2.2    Sponsored Research
		
	2.1
	In accordance with Section 2.1 of the Agreement, a collaborative research plan for the tenth year (“Tenth Year Research Plan”) of the Sponsored Research Term is attached hereto as Exhibit A and is hereby incorporated into the Agreement.  The Tenth Year Research Plan provides a budget and specific activities to be carried out by Leicester with the sponsorship of Omeros, subject to any modifications that may be agreed to in writing by Omeros and Leicester.

† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
1

		
	2.2
	In accordance with Section 2.2 of the Agreement, the Sponsored Research Term is hereby acknowledged to have been extended for an additional two years, commencing 1 October 2012 and ending 30 September 2014.  

		
	2.5
	Section 2.5 of the of the Agreement is hereby amended to provide that the total compensation to be paid by Omeros to Leicester for Sponsored Research during the tenth year of the Sponsored Research Term (i.e., 1 October 2013 through 30 September 2014) completed by Leicester in accordance with the Agreement shall be [†] as a grant-in-aid for use in supporting the salary of research staff in Professor Schwaeble’s laboratory at Leicester.

All other provisions of the Agreement, including Sections 1 through 16 inclusive, as amended above, shall continue unchanged in full force and effect.  
This Amendment is accepted and acknowledged by each party, as of the effective date set forth herein above, through the signature of its authorized representative(s) below:
	
		
	OMEROS CORPORATION
	UNIVERSITY OF LEICESTER

	By:   /s/ Gregory A. Demopulos   
Name:  Gregory A. Demopulos, M.D.
	By:   /s/ Chris A. Jones   
Name:   Chris A. Jones

	Title:    Chairman & CEO
	Title:   Head of Research Commercialization   

	Date:   September 10, 2013
	Date:   September 2, 2013

† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
2

EXHIBIT A
TENTH YEAR RESEARCH PLAN
OMEROS AND UNIVERSITY OF LEICESTER
Sponsor: Omeros Corporation
Research Institution: University of Leicester
Investigator: Prof. Wilhelm Schwaeble
Research Period: Tenth year, commencing 1 October 2013
Research Aims and Activities
Research Aims and Activities shall be as follows, or as otherwise agreed between researchers of Omeros and Leicester.
		
	•
	Support with assays and experiments

		
	•
	Collaborative research using animal models evaluating [†]

		
	•
	Collaborative research exploring the therapeutic effect [†]

		
	•
	Collaborative research exploring the therapeutic role [†]

		
	•
	Scientific expertise, advice and introductions

Budget for Tenth Year
The total consideration to be paid to Leicester for all Sponsored Research to be carried out during the tenth year of the Sponsored Research program, the amount of [†] as grant-in aid, for use in supporting the salary of research staff in Professor Schwaeble’s laboratory, payable quarterly .

† DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
3OMER-EX10.40_Oxford-Omeros-1stAmendment

EXHIBIT 10.40

FIRST AMENDMENT TO 
LOAN AND SECURITY AGREEMENT
THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 30, 2014, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “Lender” and collectively, the “Lenders”) and OMEROS CORPORATION, a Washington corporation (“Borrower”).
RECITALS
A.    Collateral Agent, Lenders and Borrower have entered into that certain Loan and Security Agreement dated as of March 5, 2014 (as amended from time to time, the “Loan Agreement”).
B.    Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.  
C.    Borrower has requested that Collateral Agent and Lenders (i) extend the time for dissolution of the Polish Subsidiaries and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein.
D.    Collateral Agent and Lenders have agreed to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
1.    Definitions.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.
2.    Amendments to Loan Agreement.  
2.1    Section 6.13 (Polish Subsidiaries).  Section 6.13 of the Loan Agreement hereby is amended and restate in its entirety to read as follows:
“6.13    Polish Subsidiaries.  Borrower shall, by no later than February 28, 2015, cause the Polish Subsidiaries to be dissolved and evidence of the same to be delivered to Agent. Borrower shall expend no more than One Hundred Twenty-Five Thousand Dollars ($125,000.00) in the aggregate in connection with such dissolution of the Polish Subsidiaries.”
3.    Limitation of Amendment.
3.1    The amendments set forth in Section 2 above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent or any Lender may now have or may have in the future under or in connection with any Loan Document.
3.2    This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

4.    Representations and Warranties.  To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:
4.1    Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;
4.2    Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;
4.3    The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date, or subsequent thereto, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;
4.4    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;
4.5    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;
4.6    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower; and
4.7    This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
5.    Counterparts.  This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.
6.    Effectiveness.  This Amendment shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders of (i) this Amendment by each party hereto and (ii) Borrower’s payment of all Lenders’ Expenses incurred through the date of this Amendment.

[Balance of Page Intentionally Left Blank]

2

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.
	
		
	COLLATERAL AGENT:

OXFORD FINANCE LLC 
	 

	By: /s/ Mark Davis
	 

	Name: Mark Davis
	 

	Title: Vice President - Finance, Secretary, and Treasurer
	 

	

LENDER:

OXFORD FINANCE LLC 
	 

	By: /s/ Mark Davis
	 

	Name: Mark Davis
	 

	Title: Vice President - Finance, Secretary, and Treasurer
	 

	

LENDER:

FLEXPOINT MCLS HOLDINGS LLC
	 

	By: /s/ Daniel Edelman
	 

	Name: Daniel Edelman
	 

	Title: Vice President
	 

	

LENDER:

MIDCAP FUNDING XI, LLC
	 

	By: /s/ Josh Groman
	 

	Name: Josh Groman
	 

	Title: Managing Director
	 

	

BORROWER:

OMEROS CORPORATION
	 

	By: /s/ Gregory A. Demopulos
	 

	Name: Gregory A. Demopulos, M.D.
	 

	Title: Chairman & CEO
	 

[Signature Page to First Amendment to Loan and Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]